# Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

> **NCT01348737** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 72 (actual)

## Conditions studied

- Alzheimer's Disease
- Safety
- Tolerability
- Blood Concentration
- Healthy Volunteers

## Interventions

- **DRUG:** AZD3839
- **DRUG:** AZD3839 Placebo

## Key facts

- **NCT ID:** NCT01348737
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2012-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01348737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01348737, "Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01348737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*